Several studies indicate that the m-opioid receptor plays a role in addiction not only to opiate drugs but also to alcohol and non-opiate addictive drugs. Our studies aim to reveal the associations between gene polymorphisms and methamphetamine (MAP) dependence/psychosis. We newly identified several polymorphisms and four substantial linkage disequilibrium (LD) blocks in the m-opioid receptor (OPRM1) gene. We found significant differences in both genotype and allele frequencies of the single-nucleotide polymorphism (SNP) IVS2 þ G691C between control (n ¼ 232) and MAPdependent/psychotic patients (n ¼ 128). There was also a significant association between IVS2 þ G691C and patients with transient psychosis. These results suggest that the OPRM1 gene variations may be a factor in development and prognosis of MAP psychosis.
Introduction
Several studies indicate that the m-opioid receptor plays a role in addiction not only to opiate drugs but also to non-opiate drugs of abuse. [1] [2] [3] [4] [5] Positive or negative regulation of the expression and/or function of the m-opioid receptor may be involved in the mechanisms of drug dependence on both opiate and non-opiate drugs of abuse. 4, 6, 7 Several single-nucleotide polymorphisms (SNPs) that cause amino-acid substitutions (non-synonymous), synonymous SNPs and SNPs in the non-coding regions and introns in the m-opioid receptor (OPRM1) gene have been reported in African-American and Caucasian populations. [7] [8] [9] Various studies of the association between frequencies of polymorphisms in the OPRM1 gene and drug dependence on opioids, alcohol or other substances in African-American, Caucasian, Hispanic, Han Chinese and Swedish populations have been reported. [10] [11] [12] [13] [14] [15] [16] [17] [18] One of these SNPs, A118G, which alters the receptor function, 10 was associated with risk for drug abuse, 14, 15 although contradictory data were also reported. 12, 13, 18 Psychostimulants including methamphetamine (MAP) exert their reinforcing effects by modulating monoaminergic transmission, of which dopamine is supposed to be the most crucial. 19 The increase in dopamine release through dopamine transporters owing to MAP is primarily responsible for the induction of its reinforcing and psychogenic effects. Opioid receptor agonists are known to affect dopamine neurotransmission 20 and to attenuate MAP-induced enhance-ment of dopamine neurotransmission. 21, 22 Naloxone, an opioid receptor antagonist, potentiated the long-lasting dopamine depletion produced by MAP. 23 Furthermore, mopioid receptor-knockout mice display reduced reward from psychostimulants. 24 Other recent studies on animals also indicate complex interactions between the dopamine and opioid systems. [25] [26] [27] [28] [29] Therefore, it is possible that variations in the opioid receptor function could produce individual differences in the vulnerability to MAP dependence and/or psychosis. In a previous study, we found a significant association between the SNP A118G and the latency of MAP psychosis, although we did not find any significant association between the vulnerability to MAP dependence/ psychosis and polymorphisms in exon 1 and its flanking regions of the OPRM1 gene in Japanese subjects. 30 Recently, we identified the 3 0 -end of the major OPRM1 transcript, MOR-1 mRNA. 31 In the present study, we extended the association studies to the downstream regions beyond the polyadenylation signal in the OPRM1 gene to identify linkage disequilibrium (LD) blocks, and examined associations between polymorphisms in the OPRM1 gene and MAP dependence and/or psychosis in Japanese.
Materials and methods

Subjects
One-hundred twenty-eight unrelated patients with MAP dependence/psychosis (99 males and 29 females, 35.971.0 years of age) meeting ICD-10-DCR criteria (F15.2 and F15.5) were used as case subjects; they were outpatients or inpatients of psychiatric hospitals. The patients had intravenously injected (n ¼ 95) or inhaled (n ¼ 33) MAP. All patients were diagnosed by two trained psychiatrists, and diagnoses were carried out on the basis of both interviews and all available information included in the hospital records. Patients were excluded if they had a clinical diagnosis of schizophrenia, another psychotic disorder or an organic mental syndrome. The 232 control subjects were mostly medical staff members who had neither personal nor familial history of drug dependence or psychotic disorders, as verified by a clinical interview. All subjects were Japanese, born and living in the northern Kyushu, Setouchi, Chukyo, Tokai and Kanto regions. This study was approved by the ethical committees of each institute of the Japanese Genetics Initiative for Drug Abuse, and all subjects provided written informed consent for the use of their DNA samples for this research.
Control samples were used to find OPRM1 gene polymorphisms in the Japanese population. We first analyzed 44 controls to find polymorphisms and then employed 188 additional samples for intron 2 (total 232), 135 for intron 3 (total 179), and 53 (total 97) and 135 (total 179) for the 3 0 untranslated region (UTR), respectively, to estimate allelic frequencies.
For the association study, we used 179 controls (139 males and 40 females, 34.671.5 years of age) for the IVS3 þ 6113, IVS3 þ 8761, IVS3 þ G5953A and IVS3 þ A6151G polymorphic sites, 213 controls (166 males and 47 females, 34.871.6 years of age) for the A118G polymorphic site (in our previous study 30 ) and 232 controls (181 males and 51 females, 35.271.8 years of age) for the IVS2 þ G691C polymorphic site. Gender, age and geographical distribution were matched without any known bias from a larger pool of control subjects.
Patient subgroups
We divided patients into two or three categories. The clinical characteristics of the subgroups were as follows:
(a) Latency of psychosis from the first MAP intake: The course of MAP psychosis varied among patients, and some patients showed psychosis sooner after the first MAP intake, as reported previously. 32, 33 The median latency was 3 years. Therefore, patients were divided into two categories based on the latency of the psychotic state after the first MAP intake: less than 3 years (n ¼ 54, average ¼ 0.83 years) or more than 3 years (n ¼ 53, average ¼ 9.98 years). (b) Duration of psychosis after the last MAP intake: Some patients showed continued psychotic symptoms despite MAP abstinence, as reported previously. 32, 33 Liability for the duration of psychosis may be determined, at least partly, by genetic variation. We previously reported that genetic variation in the dopamine transporter affects the prognosis of the psychotic state. 32, 33 Therefore, patients were divided into two categories: transient and prolonged psychosis after MAP abstinence. Patients with transient psychosis showed a reduction of psychotic symptoms within 1 month after the discontinuance of MAP consumption and the beginning of neuroleptic treatment, and prolonged psychosis continued for more than 1 month even after the discontinuance of MAP consumption and the beginning of neuroleptic treatment. In this study, 72 patients had the transient type and 43 had the prolonged type of MAP psychosis. (c) Spontaneous relapse: It has been well documented that once MAP psychosis has developed, patients in the remission phase are liable to spontaneous relapse without MAP reconsumption. 32, 33 It is postulated that a sensitization phenomenon induced by repeated consumption of MAP develops in the brains of MAP psychosis patients and is the neural basis for enhanced susceptibility to relapse. 34 Therefore, the patients were divided into two groups according to the presence (n ¼ 86) or absence (n ¼ 42) of spontaneous relapse. (d) Multiple-drug abuse: We divided MAP-dependent/psychotic patients into three groups based on drug use, MAP only (n ¼ 36), MAP plus easily accessible legal substances (e.g., alcohol, inhalants, hypnotics; n ¼ 49) or MAP plus illegal substances that are relatively difficult to access in Japan (e.g., cocaine, heroin; n ¼ 43). Note that MAP is easier to obtain in Japan than other illegal substances (e.g., cocaine, cannabis, heroin). The total number of patients in each category was not always 128 because not all data were available for several patients.
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Genotyping Genomic DNAs were extracted from peripheral blood samples by using the standard phenol extraction protocol. Northern blot analysis has revealed that the single predominant transcript of the OPRM1 gene is the approximately 14 kb long MOR-1 mRNA in the human brain. 35 We analyzed all exons of the MOR-1 mRNA and 5 0 and 3 0 intronic regions of each exon. We also analyzed the parts of the intron-containing nucleotide repeats, which were found in the database for genomic contig sequence (Genbank Accession No. NT-025741). We independently screened the amino-acid coding regions of the OPRM1 gene for sequence variations: exon 1 (290 bp) (in a previous study 30 ), exons 2-3 (353 and 521 bp), exon 4 (39 bp) and a part (from the stop codon to 2951 bp downstream from the stop codon) of the 3 0 UTR in exon 4 ( Figure 1 ). The neighboring intron sequences of each exon, intron 2 (773 bp) and some parts of intron 3 were also screened for sequence variations. In order to screen for all possible polymorphisms in the OPRM1 gene, we first analyzed all regions of all PCR products of genomic DNA from 44 control subjects by using an automated DNA sequencer. Then, the regions that included frequent polymorphisms (allelic frequency 45%) and all exons were analyzed by an automated DNA sequencer using the genomic DNAs of the remaining control subjects. The rest of the 3 0 UTR of the exon 4 (10 682 bp) and the 197 bp 3 0 -flanking region (total 10 879 bp) of the gene were similarly analyzed with DNA samples of 12 control subjects and 36 primers. Primers were designed on the basis of the reference genomic contig sequence in the National Center of Biotechnology Information (Genbank Accession No. NT-025741). The LD blocks of the polymorphisms were estimated using HaploBlockFinder Version 0.7 (http://cgi. uc.edu/cgi-bin/kzhang/haploBlockFinder.cgi). D 0 and r 2 were calculated by using the appropriate formula in the Excel program. 36 
Statistical analysis
The w 2 test was used for statistical analysis. The statistical significance level was set at a ¼ 0.05, and Bonferroni corrections were conducted on association analyses. The Hardy-Weinberg (HW) equilibrium was determined by using the w 2 test. In the analysis of LD and estimation of haplotype frequencies, genotypic data from 179 control subjects were analyzed by using the Arlequin program available from http://anthro.unige.ch/arlequin. 37 The effect size and power calculations were performed by using the G*Power program (set a value as 0.05) available from http://www.psycho.uni-duesseldorf.de/aap/projects/ gpower/. 38 
Results
Analysis of OPRM1 gene sequence variation
We analyzed exons 2-3 of the MOR-1 mRNA, parts of the introns and parts of exon 4 of the OPRM1 gene using genomic DNA samples of Japanese control subjects. We found 19 SNPs (Table 1 (1)), one dinucleotide polymorphism (DNP), IVS3 þ 6113 (GT) [11] [12] [13] [14] [15] and one polynucleotide polymorphism (PNP), a 32-base pair repeat IVS3 þ 8761 (GAC ATA TAT CAT AAT ATA TAT TAT CAT ATT AT) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] (Table  1( 2) ). None of the polymorphisms deviated from the HW expectations. There was no significant difference in allelic frequencies of polymorphisms between subjects from the Setouchi and Kanto regions, where the majority of our present subjects were born and are living (P40.4; w 2 tests). The allelic frequency of SNP IVS2 þ G691C was remarkably higher in Japanese control subjects (81.5%) than in AfricanAmerican or Caucasian populations (42.5-53.3%).
9,11 We did not find any SNP in the amino-acid coding regions of the OPRM1 gene in Japanese subjects, except the SNP A118G reported previously.
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OPRM1 genotypes and LD LD was quantified by using Lewontin's standardized coefficient D 0 ( Figure 1 ). We identified a block of LD at the OPRM1 locus that extended from intron 3 to the 3 0 UTR. The SNPs (IVS3-G8804A, TAA þ G886A, T1371C, G1670A, C2007T, A2109G, G2287A and G2395C), in intron 3 and the 3 0 UTR, which spanned an 11-kbp sequence, were observed to be in a complete LD relationship (all possible D 0 ¼ 1.000). The remaining SNPs within the region, except TAA þ A2109G (TAA þ 1260, 1709, 2274), showed a high LD, suggesting that these SNPs were also in the LD block. To determine the extent of the LD block in the 3 0 downstream region, we analyzed sequence variations up to 14 kbp downstream from the stop codon (TAA) with DNA samples of 12 control subjects. We found 42 polymorphisms in this region, and of them, 27 were in absolute LD (all possible D 0 ¼ 1.000 and r 2 ¼ 1.000, data not shown). One representative SNP (TAA þ A2109G) was selected from the polymorphisms in absolute LD. Seven SNPs in the rest of the OPRM1 gene (the 5 0 -flanking region to the SNP IVS3-G8804A) showed over 5% allelic frequency. Thus, we selected these eight SNPs to calculate D 0 values. LD analyses showed that LD relationships with significant D 0 values were observed for all possible combinations of SNPs, except for IVS3 þ G5953A and IVS3 þ G8497T (Table 2) . LD relationships with significant r 2 values were also observed for the combinations of TAA þ A2109G with IVS3 þ A6151G or IVS3 þ A8449G. The matrix of D 0 values revealed a contiguous block of high values (D 0 40.97) for four sequential markers, IVS3 þ A6151G to TAA þ A2109G. Two regions, from A118G to IVS3 þ G5807A and from IVS2 þ G691C to IVS3 þ G5953A, were also in LD blocks with high D 0 values (D 0 40.7). Interestingly, in spite of the diversity of the number of repeats, there were also significant LDs (Po0.05 by the Arlequin program) between the DNP and PNP in intron 3 and the eight SNPs (Figure 1) , as in the case of the DNP in intron 1. 26 These results suggest at least three recombination positions between A118G and IVS2 þ G691, IVS3 þ G5807A and IVS3 þ G5953A, and IVS3 þ G5953A and IVS3 þ A6151G. The following LD blocks were found in the OPRM1 gene by haplotype analysis using the HaploBlockFinder Version 0.7 program: (A) the region containing SNP A118G (around exon 1), (B) the region containing IVS2 þ C691G and IVS3 þ G5807A (at least 6.4 kb from intron 2 to about 5.9 kb 3 0 downstream from the exon 3-intron 3 junction), (C) the region containing IVS3 þ G5953A (around 6 kb 3 0 downstream from the exon 3-intron 3 junction) and (D) the region containing other SNPs (at least 23.4 from 6.1 kb 3 0 downstream from the exon 3-intron 3 junction to the 3 0 -end of exon 4).
Relationship between OPRM1 gene polymorphisms and MAP dependence/psychosis
We selected four representative SNPs (A118G, IVS2 þ G691C, IVS3 þ G5953A and IVS3 þ A6151G) from the estimated LD blocks by using HaploBlockFinder to study the association between polymorphisms in the OPRM1 gene and MAP dependence/psychosis. We found significant differences in both genotype and allele frequency at IVS2 þ G691C (w 2 test, P ¼ 0.012 and 0.011, respectively) between the controls and all patients with MAP dependence/psychosis (Table 3 ). These significances were also shown after the Bonferroni correction (corrected significance level was a ¼ 0.0125). The calculated statistical powers for the SNPs A118G, IVS2 þ G691C, IVS3 þ G5953A and IVS3 þ A6151G were 0.67, 1.00, 0.41 and 0.93, respectively. Although we further estimated the haplotypes and calculated D 0 values of these (Table 4) . We also studied the association between polymorphisms in the OPRM1 gene and the clinical parameters (latency of psychosis, psychosis prognosis, spontaneous relapse and multiple-substance abuse). The significant associations are presented in Table 5 . Based on the latency of psychosis, three SNPs (A118G, IVS2 þ G691C and IVS3 þ A6151G) showed significant differences in genotype frequencies (w 2 test, P ¼ 0.040, 0.0085 and 0.027, respectively) between the control and MAP-dependent subjects whose psychosis appeared less than 3 years from the first MAP intake. There was also a significant difference (P ¼ 0.039) in the SNP IVS2 þ G691C between the control and MAP subjects whose psychosis appeared more than 3 years after the first MAP intake, but this significance level was lower than that for the short latency group. In the prognosis of psychosis subgroups, only one SNP, IVS2 þ G691C, showed a significant difference in genotype frequency (P ¼ 0.0034) between the control and MAP-dependent subjects whose psychosis continued for less than 1 month after the last MAP intake. The association between SNP IVS2 þ G691C and the transient course of MAP psychosis was still statistically significant after the Bonferroni correction (corrected significance level was a ¼ 0.00625). Similarly, in the spontaneous relapse subgroups, only the SNP IVS2 þ G691C showed a significant difference in genotype frequency (P ¼ 0.014) between the control and MAP subjects with spontaneous relapse. In the multiple-drug abuse subgroups, SNP IVS2 þ G691C again showed a significant difference in genotype frequency (P ¼ 0.0059) between the control and MAP-dependent/ psychotic subjects who did not use any other drug. Most analyses of subcategories showed enough statistical power to detect a small size effect, although some showed weaker power (A118G for MAP-dependent/psychotic subjects who did not use any other drug, (0.31) IVS3 þ G5953A for transient prognosis of psychosis (0.29) or for no spontaneous relapse, (0.13) and IVS3 þ A6151G for later appearance of psychosis (0.16)).
Discussion
Recently, LD mapping has proved to be a powerful tool for identifying genes underlying complex clinical traits. 39, 40 The identification of at least four LD blocks in the OPRM1 gene in the present study may be useful in future association studies of polymorphisms in the OPRM1 gene with other clinical traits. The incidence of recombination may be high in the OPRM1 gene relative to other genes owing to its telomeric position on chromosome 6 (6q24-q25). However, the present study indicated that a high degree of LD still exists within the OPRM1 gene. This preservation of LD was OPRM1 gene association with MAP psychosis S Ide et al exemplified in the 3 0 region of the gene. We found absolute LD among polymorphisms in the region spanning nearly 31 kb from intron 3 to beyond the end of the 3 0 UTR (TAA þ 13.6 kb). This indicates that recombination has been remarkably rare within the block. This long and absolute LD block suggests that a set of many polymorphisms in the block may affect the expression level of the OPRM1 gene.
We found a significant association between the SNP IVS2 þ G691C in intron 2 and MAP dependence/psychosis even after the Bonferroni correction in the present study. This result provides pharmacogenetic evidence for cross-talk between the opioid and dopamine systems, as has been suggested by other studies. 20, [27] [28] [29] 41, 42 On the other hand, the SNP A118G was not significantly associated with MAP dependence/psychosis, as shown in our previous report. 30 These results, taken together with the fact that the SNP A118G was found only in the coding regions of the OPRM1 gene in Japanese subjects, could suggest that polymorphisms in the non-coding regions rather than in the coding regions of the OPRM1 gene affect MAP dependence/ psychosis.
Use of MAP induces a strong psychological dependence, and repeated use frequently results in psychotic states, symptoms of which are similar to those seen in schizophrenia of the paranoid type. 32, 34 Interestingly, the SNP IVS2 þ G691C was significantly associated with the transient course of MAP psychosis even after the Bonferroni correction. We consider that the SNPs A118G, IVS2 þ G691C and IVS3 þ A6151G tend to be associated with the short latency of MAP psychosis. Similarly, the SNP IVS2 þ G691C tended to be associated with the spontaneous relapse of MAP psychosis. Although these differences were not significant after the Bonferroni correction, we think that these tendencies reflect the existence of an association between OPRM1 polymorphisms and MAP psychosis. It has also been reported that the Bonferroni correction could be conservative for SNPs in LD. 43 Taken together, these significant differences and tendencies toward differences suggest that these SNPs might be related to the severity of MAP psychosis. In particular, the SNP IVS2 þ G691C might be related to a rapid induction of psychosis. Furthermore, the SNP IVS2 þ C691G had a tendency to be associated with single-drug abusers of MAP rather than multiple-drug abusers in the present study. This result is consistent with previous reports that the association was not observed in individuals with alcohol and drug dependence who were multiple-drug abusers. 9, 11 There are reports that increased frequency of MAP use facilitated the appearance of MAP psychosis. 44, 45 However, the information available on our subjects was not sufficient to confirm the relation between the frequency of MAP use and MAP psychosis. Although the statistical power for most analyses of subcategories of MAP psychosis was sufficient to detect an association, there is some possibility that a Type 1 error, the false rejection of the null hypothesis, exists in analyses of some subcategories with weaker powers. Further study with a larger number of subjects is required to determine the detailed association of these SNPs with the subcategories. Although it is unclear whether or not MAP dependence susceptibility has an association with the polymorphisms of the OPRM1 gene found in our present analysis using MAP dependent/ psychotic subjects, the present results of subcategory analyses suggest that the opioid system may be involved in vulnerability to MAP psychosis.
The mechanisms underlying the relationship between the SNP IVS2 þ G691C and vulnerability to MAP dependence/ psychosis have not yet been clarified. It has been revealed that the sequence variation in the amino-acid non-coding region of the murine m-opioid receptor (Oprm1) gene caused changes in the expression level of mRNA and the analgesic effect of morphine among different strains of mice. 46, 47 Furthermore, scatter plot analysis for comparison of the OPRM1/Oprm1 genes showed highly conserved regions between these species. 7, 31 One of the possible mechanisms is that the SNP IVS2 þ G691C, and/or other polymorphisms in the LD block, might be located on the sites of DNA- Twenty-thousand MAP abusers in Japan have been arrested annually in the last 30 years. The number of MAP abusers in Japan has recently been stable, although the number was larger at the end of the Second World War. 45, 48 In Japanese MAP abusers, single-drug abuse is the most common form, because MAP is relatively easy to obtain among illegal substances, whereas other illegal substances (e.g., cocaine, cannabis, heroin) are quite difficult to obtain. In Japan, the number of MAP abusers arrested was 100 times more than abusers of cocaine or cannabis. MAP abuse is not limited to specific Japanese populations. For example, high school students have recently started to use MAP casually to lose weight or just for fun. 45 Further, more than 80% of MAP abusers show MAP psychosis, and MAP may be one of the causes of the recent increase in crime. Thus, MAP abuse is a very serious and noticeable social problem in Japan. The present findings may lead to a better understanding of genetic vulnerability to MAP abuse and might provide suggestions to solve this problem.
The cross-talk between the opioid and dopamine systems underscores the role of the m-opioid receptor in dependence on non-opiate drugs. The present findings suggest that the sequence variation of the OPRM1 gene may be useful as a genetic marker to predict the development and prognosis of MAP psychosis.
